All News

Curbside Consults delivers expert perspectives from physicians outside the ob-gyn specialty to provide insight into various health issues affecting pregnant women. In this installment, we learn more about the diagnosis and management of headaches in postpartum patients.

COVID-19 updates and news to know as of December 6, 2021.

A report offers insight into how the Women’s Wellness through Equity and Leadership program performed during its pilot phase.

By July 2021, the FDA had approved or tentatively approved 470 generic versions of medications.

It is essential to expand access to all available, effective cervical cancer screening options for the most vulnerable populations. The targeted use of any particular screening modality in higher-risk populations is not supported by evidence-based guidelines; any effective screening is the priority.

Reliable compensation plans are imperative as health care becomes more complex. Hear from the experts in our new Practice Management column.

Low progesterone levels have been associated with an increased rate of miscarriage.

Here's what's coming up this week on Contemporary OB/GYN.

Wondering what you missed this week?

“This vaccine strategy has the potential to be applied to other tumor types,” said Vincent K. Tuohy, PhD, the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research at Cleveland Clinic Lerner Research Institute, and primary inventor of the vaccine.

In this episode of Pap Talk, we took you with us to the North American Menopause Society's recent Annual Meeting. Sexual health specialist Michael Krychman, MD, sat down with Brooke Faught, NP, to learn more about her work at the Women's Institute for Sexual Health, her role on the NAMS Planning Committee, and her tips for talking trauma with patients.

Patients Desiring Immediate Postpartum Sterilization Should Not Be Required to Wait 30 Days.

Olaparib, which was granted priority review by the FDA, has been shown to improve invasive disease-free survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.

Retifanlimab demonstrated encouraging antitumor activity with favorable tolerability in patients with recurrent microsatellite instability–high or mismatch repair deficient endometrial cancer, according to data from the phase 1 POD1UM-101 trial.

The US Food and Drug Administration (FDA) is currently investigating whether the new COVID-19 variant will evade current mitigation strategies and diagnostic tools.

An update from infectious disease expert, Rana F. Hamdy, MD, on the Omicron variant of COVID-19.

For girls with additional body weight, using Tanner staging to determine pubertal development may require more care.

Here's what's coming to Contemporary OB/GYN this week.

Racial and ethnic inequities persist in all 50 states.

Attention needs to be paid to the psychosocial needs of patients, especially those with poor health-related quality of life, who have little support, or are single mothers.

From 1976 to 2018, data show the prevalence of obesity in the United States increased from 6.2% to 32.7%.

Surviving a bout of cancer early in life puts children and teenagers at risk of cancers linked to human papillomavirus (HPV). A phase 2 trial examined how effective a 3-dose series was in providing protection.

Top tips and HIPAA implications.

Being informed and educated may help patients with breast cancer make a treatment decision and feel less afraid.

Discussions regarding health equity and access to care have long been implicated in breast cancer. Here, key opinion leaders discuss the latest progress in clinical trial access, digital therapeutics, and other efforts that aim to ameliorate these care gaps.

Here's what's coming up this week on Contemporary OB/GYN.

The trial is the first in the world offering this City of Hope-developed investigational therapy to patients with the hope of one day improving survival for people with triple-negative breast cancer.

"We're moving from an era where it was all based on judgment, and experience, to an era where treatments will be based on firm evidence of the structural failures present in each patient," says Contemporary OB/GYN Advisory Board member John O. L. DeLancey, MD.